Current Role of Ivabradine in Stable Coronary Artery Disease Without Heart Failure

被引：0
|
作者：
Mateo Porres-Aguilar
Oscar C. Muñoz
Aamer Abbas
机构：
[1] Texas Tech University Health Sciences Center/Paul L. Foster School of Medicine,Department of Internal Medicine
[2] Texas Tech University Health Sciences Center/Paul L. Foster School of Medicine,Division of Cardiovascular Diseases
来源：
Current Cardiology Reports | 2016年 / 18卷
关键词：
Coronary artery disease; Ivabradine; Heart failure; Heart rate;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Increase in heart rate represents a significant contribution in the pathophysiology of coronary artery disease and heart failure, by promoting atherosclerotic process and endothelial dysfunction. Thus, it negatively influences cardiovascular risk in the general population. The aim of this review is to analyze the current, controversial, and future role of ivabradine as an anti-anginal agent in the setting of coronary artery disease without heart failure. Ivabradine represents a selective heart rate-lowering agent that increased diastolic perfusion time and improving energetics in the ischemic myocardium.
引用
收藏
相关论文
共 50 条
  • [1] Current Role of Ivabradine in Stable Coronary Artery Disease Without Heart Failure
    Porres-Aguilar, Mateo
    Munoz, Oscar C.
    Abbas, Aamer
    [J]. CURRENT CARDIOLOGY REPORTS, 2016, 18 (02) : 1 - 4
  • [2] Ivabradine in Stable Coronary Artery Disease without Clinical Heart Failure
    Fox, Kim
    Ford, Ian
    Steg, Philippe Gabriel
    Tardif, Jean-Claude
    Tendera, Michal
    Ferrari, Roberto
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (12): : 1091 - 1099
  • [3] Ivabradine in the treatment of heart failure and coronary artery disease
    Verschuren, J. J. W.
    Jukema, J. W.
    [J]. NETHERLANDS HEART JOURNAL, 2011, 19 : 20 - 22
  • [4] Ivabradine: a new frontier in the treatment of stable coronary artery disease and chronic heart failure
    Gammone, M. A.
    Riccioni, G.
    D'Orazio, N.
    [J]. CLINICA TERAPEUTICA, 2020, 171 (05): : E449 - E453
  • [5] Ivabradine in the management of coronary artery disease with or without left ventricular dysfunction or heart failure
    Ferrari, Roberto
    [J]. EUROPEAN HEART JOURNAL SUPPLEMENTS, 2015, 17 (0G) : G24 - G29
  • [6] Ivabradine in Stable Coronary Artery Disease
    Stulc, Tomas
    Ceska, Richard
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (25): : 2435 - 2435
  • [7] Ivabradine, coronary artery disease, and heart failure: beyond rhythm control
    Scicchitano, Pietro
    Cortese, Francesca
    Ricci, Gabriella
    Carbonara, Santa
    Moncelli, Michele
    Iacoviello, Massimo
    Cecere, Annagrazia
    Gesualdo, Michele
    Zito, Annapaola
    Caldarola, Pasquale
    Scrutinio, Domenico
    Lagioia, Rocco
    Riccioni, Graziano
    Ciccone, Marco Matteo
    [J]. DRUG DESIGN DEVELOPMENT AND THERAPY, 2014, 8 : 689 - 700
  • [8] lvabradine in stable coronary artery disease without heart failure (SIGNIFY study)
    Rodriguez Davila, M. A.
    [J]. REVISTA CLINICA ESPANOLA, 2015, 215 (02): : 131 - 131
  • [9] From coronary artery disease to heart failure: potential benefits of ivabradine
    Tardif, Jean-Claude
    Berry, Colin
    [J]. EUROPEAN HEART JOURNAL SUPPLEMENTS, 2006, 8 (0D) : D24 - D29
  • [10] Effect of ivabradine on heart rate variability in patients with stable coronary artery disease
    Stewart, R. A. H.
    Armstrong, P. W.
    Chiswell, K.
    Hagstrom, E.
    Held, C.
    Krug-Gourley, S.
    Ryan, C. M.
    Stebbins, A.
    Wallentin, L.
    White, H. D.
    [J]. EUROPEAN HEART JOURNAL, 2015, 36 : 1088 - 1088
12345